-

$undefined

N/A

(N/A)

Acelyrin Inc. NasdaqGS:SLRN Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Location: 4149 Liberty Canyon Road, Agoura Hills, CA, 91301, United States | Website: https://www.acelyrin.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-176.4M

Cash

410.6M

Avg Qtr Burn

-71.39M

Short % of Float

5.22%

Insider Ownership

7.14%

Institutional Own.

92.06%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lonigutamab Details
Thyroid Eye Disease , Eye disease

Phase 3

Initiation

Izokibep Details
Axial spondyloarthritis

Failed

Discontinued

Izokibep Details
Psoriatic arthritis

Failed

Discontinued

Izokibep Details
Uveitis , Eye disease

Failed

Discontinued

SLRN-517 Details
Allergy, Inflammatory disease, KIT/Mast cell diseases

Failed

Discontinued

Izokibep Details
Hidradenitis suppurativa

Failed

Discontinued